Pancreatic Cancer Research

ResearcherThe Royal Melbourne HospitalActive in the last 2 years

Benjamin P. T. Loveday

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8179-2182; OpenAlex author ID A5071390444. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers

Papers 17

  1. Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study. Co-author DOI 10.1097/ms9.0000000000004919↗
  2. Timeliness of Care and Treatment Patterns for Pancreatic Cancer in Victoria, Australia: Comparison With Optimal Care Pathways Targets. Co-author DOI 10.1111/ans.70705↗
  3. Stakeholder Consensus Selection of Data Elements and Indicators for a Pancreatic Cancer Surgical Outcomes Registry in Australia and Aotearoa New Zealand: Modif… Last author DOI 10.1111/ans.70789↗
  4. Surgery for Locally Advanced Pancreatic Ductal Adenocarcinoma: Selection of Patients and Surgical Technique. First author DOI 10.1159/000550333↗
  5. Relationship between pancreatic cancer resection rate and survival at population level: systematic review. Last author DOI 10.1093/bjsopen/zraf007↗
  6. Re: Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis. Last author DOI 10.1111/ans.19370↗
  7. A Scoping Review on the Data Utility, Clinical Impact, and Cost of Multidisciplinary Team Meetings for Pancreatic Cancer. Last author DOI 10.1111/ans.70262↗
  8. Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world reg… Co-author DOI 10.1186/s12889-025-23925-4↗
  9. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Co-author DOI 10.1016/j.esmorw.2023.100022↗
  10. Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. Co-author DOI 10.1038/s41416-024-02619-5↗
  11. Filling the information void for the benefit of patients: why AANZ need a population-based clinical quality registry for pancreatic cancer surgery. Last author DOI 10.1111/ans.19265↗
  12. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  13. Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. First author DOI 10.1111/ans.17787↗
  14. Impact of pancreatic enzyme replacement therapy on short- and long-term outcomes in advanced pancreatic cancer: meta-analysis of randomized controlled trials. Co-author DOI 10.1080/17474124.2021.1884544↗
  15. The Impact of the Depth of Venous Invasion on Survival Following Pancreatoduodenectomy for Pancreatic Cancer: a Meta-analysis of Available Evidence. Co-author DOI 10.1007/s12029-019-00248-3↗
  16. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. First author DOI 10.1111/ans.14764↗
  17. Pancreatic cancer: An update on diagnosis and management. Co-author DOI 10.31128/ajgp-06-19-4957↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth Lockie · 4 shared papers, 2024–2026 · strength 1.27
  2. John Raymond Zalcberg · 4 shared papers, 2024–2026 · strength 1.27
  3. Belinda Lee · 6 shared papers, 2022–2026 · strength 1.19
  4. Sanjay Pandanaboyana · 5 shared papers, 2019–2026 · strength 1.11
  5. Benjamin N. J. Thomson · 6 shared papers, 2019–2026 · strength 1.09
  6. Mehrdad Nikfarjam · 5 shared papers, 2024–2026 · strength 1.00
  7. Peter Gibbs · 5 shared papers, 2022–2026 · strength 0.93
  8. John Albert Windsor · 3 shared papers, 2019–2026 · strength 0.67
  9. Sam Banks · 3 shared papers, 2024–2026 · strength 0.60
  10. Savio George Barreto · 2 shared papers, 2019–2026 · strength 0.52
  11. Matthew Burge · 2 shared papers, 2024–2026 · strength 0.39
  12. Anubhav Mittal · 1 shared paper, 2026 · strength 0.39
  13. Shehara Ramyalini Mendis · 2 shared papers, 2024–2025 · strength 0.35
  14. Hyun Soo Ko · 2 shared papers, 2022–2024 · strength 0.32
  15. Adrian M. Fox · 2 shared papers, 2024 · strength 0.32
  16. Yat Hang To · 2 shared papers, 2024 · strength 0.32
  17. Jonathan Koea · 1 shared paper, 2026 · strength 0.29
  18. Manju Dashini Chandrasegaram · 1 shared paper, 2026 · strength 0.29
  19. Andrew J. Metz · 1 shared paper, 2026 · strength 0.29
  20. Que Wuttivat Sabmeethavorn · 1 shared paper, 2025 · strength 0.28
  21. Bathiya Ratnayake · 2 shared papers, 2020–2021 · strength 0.28
  22. Silja Schrader · 1 shared paper, 2026 · strength 0.26
  23. Jon D. Emery · 1 shared paper, 2026 · strength 0.26
  24. Amitesh Chandra Roy · 1 shared paper, 2026 · strength 0.24
  25. Eden Mane · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.